Member Info for KingHomerJ

People can say what they want - it’s always gonna be the case……and unavoidable on any shares….always traders and each to their own.

I have posted enough about the facts and fundamentals…..it’s there to see.

Seemingly these days people can’t be bother to do any research…..horse to water and all that.

There will be more news before the financial year end which is this month as well as a DoseMe update & Beyond blood soon.

Market is aware there is news on a lot of front this Month….

NHS Collaboration and Support

Physiomics has secured significant backing from UK public health bodies, including Innovate UK and the National Institute for Health and Care Research (NIHR). The company is collaborating with Blackpool Teaching Hospitals NHS Foundation Trust and Beyond Blood Diagnostics on the PREDICT-ONC project. This project aims to refine and evaluate a personalised dosing tool for G-CSF, focusing on breast cancer patients undergoing chemotherapy. The trial has received both regulatory and ethical approval and is expected to run until late 2025 .

Clinical Validation and Expansion

The PREDICT-ONC project builds upon insights from the earlier PARTNER study, which demonstrated the tool's ability to predict neutropenia levels and the effects of G-CSF in prostate cancer patients . This progression indicates a growing confidence in the tool's clinical utility.

Pathway to NHS Integration

While the tool is not yet in routine NHS use, the ongoing clinical trials and regulatory approvals are crucial steps toward its integration. Successful outcomes from these studies could pave the way for broader adoption across NHS oncology departments, especially in managing chemotherapy-induced neutropenia.

sharecast.com

In summary, Physiomics' precision dosing tool is on a clear trajectory toward NHS adoption, supported by clinical validation and strategic partnerships, which will lead to significant value to Physiomics while reducing NHS costs and supporting patient outcome.

Burt....NHS adoption and its minimum £50million alone....and the precision dosing tech can save Billions....

its all there in black and white.....oh and the trial is live and is due to finish end of 2025

The Trial is on GCFS…..

The software was initially developed to support clinicians make cancer chemotherapy (docetaxel) dosing decisions, helping to optimise dosing for individual patients to improve patient outcomes. However, as a result of the PARTNER study (completed in January 2023), a second utility was observed, in that the software could be used to support the dosing of an expensive biological drug GCSF. This drug is routinely used in many countries to counteract the toxic effect chemotherapy has on patient's white blood cells - a condition known as neutropenia.

This covers ALL TYPES OF CANCER

GCSF is most expensive treatment on earth

The market is anticipated to reach between $9.17 billion and $12.4 billion by 2032

Laura you are forgetting one key thing here..

PYC are currently in a LIVE trial for there precision dosing tool….which is due to finish at the end of the year…..

Any NHS adoption of the device which I’m confident will happen as there has been a significant amount of funding and government policy around this…..this is a company maker on its own and will generate tens of millions annually.

Basil 8p would be very very easy achieved when you look at PYC pipeline and actually revenue Vs other companies that are 15-25 times higher with zero pipeline / products / contracts / revenue/ trials and integrations

The collaboration between Physiomics and DoseMeRx in personalized chemotherapy dosing, particularly for docetaxel, presents significant revenue growth opportunities for both companies.

Physiomics' personalized dosing software, initially available on a research basis, is poised to become a paid feature on the DoseMeRx platform. This shift is expected to establish a recurring revenue stream through licensing or subscription models, Integration with DoseMeRx provides Physiomics access to a broader clinical user base across the US and Europe.

The global oncology market is projected to exceed $500 billion by 2030, with a strong emphasis on personalized medicine. This trend underscores the commerciality for Physiomics' personalized dosing solutions.

The company secured a £161,580 contract with a UK-based biotech client specializing in AI-driven therapy development. This project utilizes Physiomics' proprietary Virtual Tumour technology to guide dosing regimens for an oncology asset, with completion expected over the next five months.

DoseME

From pervious RNS,

“The company has a deeper relationship with DoseMe to develop develop additional models to be implemented across all of there platform”

DoseMe’s platform has hundreds of thousands of users across, North and South America, Europe, Turkey and Asia

The company was valued at £16 million 3 years ago….

That valuation didn’t include…..

Dosemerx integration and the addition of PYC looking at Dosemerx other assets

Beyond Blood (valued at 30 million) trial with NHS Blackpool which is currently ongoing with the dosing app….

The dosing app which was originally designed for prostate cancer is now being used for all areas of cancer linked to the expensive GCSF.

(Update on this very very soon)

Biostatistics pipelines and new revenue streams

Record revenues and contracts won

Multi year contracts into 2027

Contracts with Major Pharmaceutical (Servier) running into December 2025 - annual revenue of £5 Billion

I mean this is the 2nd contract and this contract is a 12 month contract - they have a huge pipeline and openly state on there website they focusing on using companies like PYC……it’s there in black and white

At Servier, we have chosen to focus on a number of therapeutically promising technological platforms in order to fully tap their potential: small molecules, monoclonal antibodies, and antisense oligonucleotides (ASOs). These building blocks are expected to pave the way for new treatments to address the needs of patients who currently have few or no treatments available.

At Servier, we strongly believe that these technologies are the keystone for developing next-generation therapeutic solutions.

Through our focus on these cutting-edge technologies, Servier researchers can unlock their full potential to address the needs of patients, particularly those with rare cancers and neurological diseases.

Servier has an annual revenue £5 Billion and listed in the top 20 pharmaceutical companies globally and the second highest in France.

In December 2024, Physiomics announced the awarding of a new contract by Servier, valued at £157,000. This project involves applying Pharmacokinetic-Pharmacodynamic (PKPD) modeling to inform dosing and scheduling decisions for a novel cancer treatment combination. Notably, this collaboration marks the first incorporation of an Antibody-Drug Conjugate (ADC) into Physiomics' Virtual Tumour platform, highlighting the expanding scope of their partnership . This contract is due to end December 2025.

The partnership with Servier is a strategic milestone for Physiomics, reflecting its growing influence in the oncology sector. The integration of ADCs into their modeling platform positions Physiomics at the forefront of personalized cancer therapy development. Additionally, the collaboration enhances Physiomics' credibility and visibility within the pharmaceutical industry, potentially leading to further opportunities with other top global pharmaceutical companies.

Burt….personally I can this MC being multiples and multiples of current MC….MC was £16million 3 years ago and we are way way way down the line on numerous fronts…..

Personally I can see and DoseMe & Beyond Blood update soon aswell as numerous news before the financial year end (June 25) maybe as soon as this week…….

They picked it up from Sky News desk…….

Stranger things have happened

Evopoint to receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved -

Physiomics plc is not directly developing the drug XNW27011. However, the company has been involved in supporting its development through pharmacokinetic-pharmacodynamic (PKPD) modelling

Https://www.prnewswire.com/news-releases/astellas-enters-exclusive-license-agreement-with-evopoint-biosciences-for-xnw27011--a-novel-clinical-stage-antibody-drug-conjugate-targeting-cldn18-2--302469022.html